Related Experiment Videos
Current treatment options for chronic granulomatous disease
1Immunology Department, Great Ormond Street Children's Hospital NHS Trust, Great Ormond Street, London, WC1N 3JH, UK. d.goldblatt@ich.ucl.ac.uk
Expert Opinion on Pharmacotherapy
|June 27, 2002
Summary
Chronic granulomatous disease (CGD) management focuses on preventing infections with antibiotics and antifungals. Emerging therapies like gene therapy offer potential cures for this rare genetic disorder.
Area of Science:
- Immunology
- Genetics
- Infectious Diseases
Background:
- Chronic granulomatous disease (CGD) is a rare inherited disorder affecting phagocytic cells.
- CGD patients exhibit increased susceptibility to catalase-positive bacterial and fungal infections, notably Aspergillus species.
- Granuloma formation is a characteristic pathological feature of CGD.
Purpose of the Study:
- To outline the current therapeutic strategies for managing chronic granulomatous disease.
- To discuss the role of prophylactic antibacterial and antifungal agents.
- To explore emerging and potential curative treatments for CGD.
Main Methods:
- Review of established and novel therapeutic approaches for CGD.
- Analysis of prophylactic regimens, including trimethoprim sulfamethoxazole and itraconazole.
- Evaluation of immunomodulatory agents like interferon-gamma (IFN-γ).
Main Results:
- Antibacterial and antifungal prophylaxis are the cornerstone of CGD therapy.
- Trimethoprim sulfamethoxazole and itraconazole are standard for bacterial and fungal prevention, respectively.
- Interferon-gamma aids in managing refractory infections.
Conclusions:
- Current management relies on prophylaxis, with specific agents for bacterial and fungal infections.
- Novel antifungal agents show promise for invasive Aspergillus infections.
- Bone marrow transplantation and gene therapy represent potential curative options for CGD.